In 2018 Dr, Liau published a peer-reviewed trial description that reiterated the PFS primary endpoint and had NO discussion of the confounding. Only the NWBO's SEC filing on 3/31/21 finally reported reported the PFS confounding.
All it took was unblinding the data and declaring the PFS confounded (when it failed) to replace it with the secondary endpoint of naïve OS. So they got all the clinicians to buy off on it. Then they data dredged the recurrent OS as they had no other endpoints.
The confounding of the PFS metric was NOT reported in any company communications during the trial. They had trouble enough with the FDA trial stoppage. They didn't publicly report what the cause of that was.
Claim all you want -- but where's the public communication? Even the head clinician was reiterating the PFS endpoint in 2018 after almost all the data was gathered.
Market Data 
Markets 
AI
